Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

January 31, 2009

Conditions
Crohn's Disease
Interventions
DRUG

infliximab

5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6

DRUG

placebo

placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6

Trial Locations (1)

15261

University of Pittsburgh, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

University of Pittsburgh

OTHER